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Purpose: We quantified mRNA expression of candidate genes for proliferation (KIF14 and E2F3) in a large
retinoblastoma tumor cohort and associated with disease phenotype.
Methods: KIF14 and E2F3 mRNA expression was quantified by real time PCR in 57 retinoblastoma (RB) tumors, 3 RB
cell lines, and control samples that included 4 each fetal, age-matched, adult retinas. Immunohistochemistry was done to
confirm KIF14 and E2F3 protein expression in tumor cells. The mRNA expression levels were correlated with disease
phenotypes including the significance of chemotherapy on tumors.
Results: There was statistically significant overexpression of KIF14 and E2F3 mRNA in tumors compared with control
retinas (p<0.0001). Further, E2F3 also showed a significant overexpression compared to RB cell lines (p=0.01).
Immunohistochemistry confirmed KIF14 and E2F3 protein overexpression in tumor cells. KIF14 had significant mRNA
overexpression with older age (p=0.01) in presenting patients and in unilateral RB patients (p=0.04). Chemotherapy-
treated tumors showed a significant decrease in KIF14 and E2F3 expression compared to untreated tumors (p<0.01 and
0.001, respectively).
Conclusions: This report confirms significant mRNA overexpression of KIF14 and E2F3 together in a large cohort of
RB tumors. The decreased expression in chemotherapy treated cases needs further validation in a large chemotherapy-
treated cohort.
Recent advancements in retinoblastoma (RB) research
yielded vital information on additional events after two hits in
RB progression. 1q31–32 (62%) and 6p22 (43%) are the
regions more widely shown to cause gain of site in RB tumors
[1]. Studies have shown the KIF14 gene in the 1q31–32 region
[2] and the E2F3/DEK genes in the 6p22 region [3,4] are the
potential candidate genes that cause the gain of site.
KIF14, a mitotic kinesin gene, has been predicted to be a
possible oncogene in the 1q region, and was found to
overexpress by more than 2 orders of magnitude in RB [2].
Further, KIF14 overexpression has a strong correlation with
age at diagnosis in RB, and probably represents the amount
of chromosomal/genetic instability required for tumor
formation [5]. The level of KIF14 has been correlated with
mitotic progression in the cell cycle, and this protein, along
with the microtubule-bundling protein PRC1 and citron
kinase, with which it interacts, plays an important role in
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cytokinesis during midbody formation and completion of
cytokinesis [6].
E2F, in conjunction with its dimerization partner,
regulates genes that play a role in DNA replication [7,8].
Reports show that tumors with complete gain at loci on
chromosome 6p were diagnosed significantly later with a
median age at diagnosis [3]. Chromosome 6p gain is also
common in bladder cancer and associated with an elevated
risk of progression of bladder cancer [9]. The objective of the
present work was to quantify the mRNA expression of KIF14
in a large cohort of 57 RB tumors, which includes 28 tumor
samples previously reported by us ( [5]; used with publisher’s
permission), along with E2F3, in the same cohort, and do a
phenotype correlation.
METHODS
Clinical samples: The study adhered to the Declaration of
Helsinki. This study was conducted at the Medical Research
Foundation and Vision Research Foundation, Sankara
Nethralaya, India, and was approved by the institutional ethics
boards. Informed consent was obtained from the parents of
RB patients for the research use of RB tumor samples obtained
from enucleated eyes removed as a part of treatment. Normal
human retinas were obtained from the C.U. Shah Eye Bank
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(Medical Research Foundation, Sankara Nethralaya,
Chennai) and the Lions Eye Bank (The Regional Institute of
Ophthalmology, Chennai), after proper approval and the
eyeballs were examined under the microscope to rule out any
pre-existing pathology. Two fetal retinas were commercially
purchased (Advanced Bioscience Resources, Inc., Alameda,
CA), after proper ethical clearance and 2 were gifted by Rod
Bremner, (Toronto Western Research Institute,
Toronto,Canada). In total, 57 RB tumor samples were
collected from eyes removed as a part of therapy in patients
with age at diagnosis between 1 to 84 months. Out of the 57
samples, 2 samples were obtained from patients who
underwent chemotherapy before enucleation. Further, out of
57 samples studied, KIF14 mRNA expression data of 28
samples previously published by us [5] were selected for this
study.
RNA extraction and reverse transcription: Total RNA was
extracted from tumors and normal healthy retina by the
guanidine isothiocyanate and chloroform method (TRI
Reagent®; Sigma Aldrich, Bangalore, India) as per
manufacturer’s instructions. All RNA samples were treated
with Turbo DNase® (Ambion, Genetix Biotech Asia Pvt. Ltd,
Chennai, India). For all samples, 1 μg total RNA was used to
synthesize first-strand cDNA using SuperScript II® reverse
transcriptase (Invitrogen, Joyvel, Chennai, India) and random
primers.
Real-time RT–PCR analyses: TaqMan gene expression assays
were used to quantify the mRNA expression of KIF14
(Hs00978216_m1) and E2F3 (Hs00605457_m1) normalized
against two endogenous controls: GAPDH
(Hs99999905_m1) and HPRT (Hs99999909_m1; Applied
Biosystems, LabIndia, Chennai, India). Quantification of
gene expression was performed in triplicate in a 20 μl volume
in 96 well plates on an ABI prism 7300 real time PCR System.
Each reaction included 1X TaqMan primer probe mix, 1X
TaqMan Universal PCR Master Mix, and 100 ng cDNA.
Cycling conditions were as follows: 2 min at 50 °C, 10 min at
95 °C, and 40 cycles of 15 s at 95 °C plus 1 min at 60 °C. The
normalized gene-of-interest (GOI) expression levels were
calculated as follows: Ct values were transformed to quantities
by using the comparative Ct method. Here, the calibrator’s
(F2) quantities for each gene were set to 1. The normalization
factor for each sample was calculated by taking the geometric
mean of the two housekeeping genes (GAPDH and HPRT)
using geNorm software. The normalized GOI expression
levels were calculated by dividing the raw GOI quantities for
each sample by the appropriate normalization factor.
Immunohistochemistry: Paraffin sections of RB tumors and
non-neoplastic retina from a 52-year-old donor’s eyeball
(5 µm thick) were dewaxed and rehydrated. Antigen retrieval
was performed to unmask the antigens for better antigen
antibody interactions. Following the dewaxing and
rehydration protocol, the slides were immersed with preheated
citrate buffer (0.1 M Tri sodium citrate and 0.1 M citric acid
with a pH 6.0) in the pressure cooker on the hot plate. The
slides were exposed to steam inside pressure cooker until two
whistles are completed. Immediately, the pressure cooker was
subjected to cooling under running tap water. Endogenous
peroxidase activity was blocked for 10 min with 3% H2O2 in
H2O, and the slides were incubated with 1:75 rabbit polyclonal
affinity purified anti-KIF14 antibody in Tris buffer, pH 7.6
(BL358; Bethyl Laboratories, Genuine Chemical Corp, India)
and with 1:75 mouse monoclonal anti-E2F3 antibody in Tris
buffer, pH 7.6 (Upstate, Millipore, Billerica, MA), a kind gift
from Rod Bremner (Toronto Western Research Institute,
Toronto, Canada) separately. Immunostaining was performed
using Dako LSAB+system-horseradish peroxidase
(Dakocytomation, Glostrup, Denmark). The reaction was
revealed by 3, 3′-diaminobenzidine tetrahydrochloride
(Dakocytomation) and counterstained with hematoxylin. For
the negative control, immunostaining was done without
primary antibody.
Immunoanalysis: Evaluation of immunostaining in tumor
cells was objectively performed by two investigators (J.M.
and K.M.) in 6 tumors from the cohort. Ten tumor fields were
randomly scanned for protein expression under 40X, and
percentage of positive tumor cells was noted for each field.
Finally, the average expression was calculated for the entire
slide from the 10 values. Depending on the percentage of
positive cells, 4 categories were established: 0, no positive
cells; 1+, positive cells in less than one-third; 2+, positive cells
in 33%–67% and 3+, positive cells in more than two-thirds of
total tumor cell population [10].
Statistical analysis: mRNA expression levels of KIF14 and
E2F3 in tumors were separately compared to those in RB cell
lines, fetal, age-matched and adult retinal controls using the
Mann–Whitney U test. Associations between phenotypic
characteristics (median age at diagnosis and disease duration)
were also studied by Pearson’s coefficient of correlation. The
influence of familial tumors, laterality, differentiation, and
invasion on gene expression was assessed. The expression
levels in tumors exposed to chemotherapy were analyzed
separately for significance against untreated tumor samples.
All analyses were performed with SPSS version 13.0 (SPSS
Inc., Chicago, IL) and p<0.05 was considered significant.
RESULTS
Quantification of KIF14 and E2F3 mRNA expression levels
in tumor and control samples: We quantified KIF14 and E2F3
mRNA in 57 tumors samples, of which 2 had received
chemotherapy before enucleation (Figure 1). For controls,
KIF14 and E2F3 mRNA levels were determined in 4 fetal
(18–20-weeks gestation), 4 age-matched (13–18 months old),
4 adult retinas (21–60 years), and 3 RB cell lines (Y79, WERI,
and RB381). Levels were normalized to 2 housekeeping
genes, GAPDH and HPRT. The average fold change between
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all tumors, as well as the subsets of chemotherapy untreated
tumors with each control set was calculated, as well as that
between the untreated and treated tumor sets (Table 1). There
was statistically significant overexpression of KIF14 and
E2F3 mRNA expression in tumors compared to fetal retinal,
age-matched and adult control retinas (p<0.0001). There was
a significant overexpression of E2F3 expression compared to
RB cell line controls (p=0.01). The chemotherapy-treated
subset showed a significant decrease in the expression of
KIF14 (p<0.01) and E2F3 (p<0.001) compared to untreated
tumors.
Phenotype correlation: We examined whether there was a
correlation between KIF14 and E2F3 mRNA expression
levels in the 55 untreated tumors and various tumor
phenotypes (Table 2). Samples from the 2 patients who
received chemotherapy before enucleation were excluded
from further analysis. There was a statistical increase in KIF14
expression with older age at presentation (p=0.01) and in
unilateral RB patients (p=0.04). No correlation was found
between KIF14 mRNA expression and differentiation,
familial tumors, invasion of the tumor into the choroid and
optic nerve, or the duration of the disease (defined as the
period between identification of symptoms to the time of
enucleation). Further, there was no correlation between the
mRNA expression of E2F3 and different tumor phenotypes
(Table 2).
Immunoreactivity of KIF14 in non-neoplastic retina and RB
tumor cells: No immunoreactivity for KIF14 or E2F3 was
noted in the control healthy retina (Figure 2A,D), whereas
KIF14 expression was localized to the nucleus and cytoplasm
in tumor cells (Figure 2B,C), and E2F3 expression was
localized to the nucleus (Figure 2E,F). All 6 tumors, which
were stained, showed heterogeneous expression of KIF14 (2+
staining) and E2F3 (3+ staining).
DISCUSSION
After knocking out the tumor suppressor RB1 gene in the
tumor-prone retinal cells, RB has to progress into full-fledged
Figure 1. Quantification of KIF14 and E2F3 mRNA expression levels in tumor and control samples calibrated to fetal control retina (F2).
There was statistically significant overexpression of KIF14 and E2F3 mRNA expression in tumors compared to fetal retinal, age-matched
and adult control retinas (p<0.0001). There was a significant overexpression of E2F3 expression compared to RB cell line controls (p=0.01).
The chemotherapy-treated subset (last two unshaded bars) showed a significant decrease in the expression of KIF14 (p<0.01) and E2F3
(p<0.001) compared to untreated tumors. Error bars represent standard error of the relative fold expression levels of KIF14 and E2F3.
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malignancy. This is achieved by triggering oncogenes, which
can help in multiplication of the tumor cells. Different cancers
take different routes for progression based on genetic
instability. Comparative genomic hybridization and
microarray-based PCRs have been narrowed to a few
oncogenes, which probably helps RB to progress [11-14].
KIF14 and E2F3 may represent important pro-oncogenes,
TABLE 2. SIGNIFICANCE OF KIF14 AND E2F3 MRNA EXPRESSION LEVELS
COMPARED TO PHENOTYPE OF TUMORS.
Phenotype
Significant
variation in fold
KIF14 E2F3
Age at diagnosis (median 24
months)
0.01* 0.67
Duration (median 1.5 months) 0.34 0.55
Laterality 0.04* 0.28
Differentiation 0.31 0.91
Familial 0.63 0.19
Invasion 0.81 0.51
*There was a statistical increase in KIF14 expression with
older age at diagnosis (p=0.01) and in unilateral RB patients
(p=0.04).
which have been seen to be deregulated in most RB tumors.
By real time PCR, we found an overexpression of these 2
oncogenes in all tumors studied compared to fetal, age-
matched and adult retinas. The sensitivity of real time PCR is
perhaps higher compared to the previously used techniques to
identify the amount and percentage of tumors, which showed
deregulation in the genes studied. Nucleocytoplasmic
localization of KIF14 possibly  represent  its  cytoplasm
to  the  nucleus  mobilization  during  spindle  formation as
shown byprevious study [15]. This in addition to the nuclear
localization of E2F3 may represent the functional intactness
of both proteins in tumor cells. These 2 oncogenes act at
different points in the cell cycle to accomplish proliferation
after deregulation of pRB. E2F3 acts as a transcriptional
activator of genes that are derepressed following transition
through the RB1-dependent G1/S-phase cell cycle checkpoint
[16], and play a role in DNA replication. KIF14 plays an
important role during mitosis [6,15], and overexpression
results in error-prone mitosis and tumor progression.
As seen with our earlier report [5], phenotype correlations
revealed a statistically significant increase in mRNA
expression of KIF14 in patients at older age at diagnosis.
There was a statistically significant increase in KIF14 mRNA
TABLE 1. KIF14 AND E2F3 MRNA EXPRESSION IN TUMORS COMPARED TO CONTROL SAMPLES.
Control
Gene                 Average
expression          fold changea
Increased                         Decreased
  # of             Fold
tumors           upa
  # of                Fold
tumors            downa
Fetal retina compared
to chemotherapy
untreated tumors
KIF14 7.0 <0.0001* 57 1.1–29.1 0 -
E2F3 20.4 57             3–110.7
Age matched retina
compared to
chemotherapy
untreated tumors
KIF14 239.7 57             40–1000 0 -
E2F3 50.3 57            1.1–280.5             0
Adult retina compared
to chemotherapy
untreated tumors
KIF14b - - - - -
E2F3 17.8 56              2.6–96.4              1
Cell lines compared to
chemotherapy
untreated tumors
KIF14 2.5 0.13 44 1.1–10.6 13 1–2.3
E2F3 5.0 0.01* 54             1.1–27.3               3 1–1.3
Tumor after
chemotherapy
compared to
chemotherapy
untreated tumors
KIF14 34.9 0.01* 53 1.3–23.7               2 1.1–3.5
E2F3 5.8 0.001*                  55            5.8–145.8 0
Statistical significance of KIF14  and E2F3  mRNA expression in tumors compared to control samples. aFold change is expressed
relative to the median of the control samples. bShows infinity value against adult retina controls. *Statistically significant.
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p value
0
1.1
-
expression with unilateral RB compared to bilateral RB
(p=0.04), which was not reported in our earlier study. As the
median age at diagnosis of unilateral RB is late compared to
bilateral RB, this correlates with a significant increase in the
levels of KIF14 mRNA expression in older age at
presentation. Probably unilateral late onset tumors need more
genetic instability for tumor progression, as retinal cells are
in the final stage of terminal differentiation. E2F3 mRNA
expression levels did not show statistical significance with
different phenotype variables. As KIF14 and E2F3 genes have
a role in cell proliferation, and the severity of RB is related to
the rate of proliferation of the tumor, even with known bias in
the patient’s history, duration of the disease was calculated for
individual patients and correlated with the relative KIF14 and
E2F3 mRNA expressions. No significant variability in KIF14
and E2F3 mRNA expression was noted with increase or
decrease in disease duration.
The highly statistically significant decrease in the levels
of KIF14 mRNA expression (p<0.01) and E2F3 mRNA
expression (p<0.001) in chemotherapy-treated cases shows
the effect of chemotherapy on proliferative tumor cells. This
needs further validation in more numbers of chemotherapy
treated tumor samples. In addition to the aforedescribed
finding, the statistical increase in the mRNA expression of
E2F3 in fresh tumors compared to RB cell lines (p=0.01)
discourages the use of RB cell lines to evaluate this gene for
further studies.
This is the first report on the levels of two important
candidate genes (KIF14 and E2F3) for proliferation of RB
tumor simultaneously done in a larger cohort with phenotype
association.
ACKNOWLEDGMENT
This work was supported by Oil and Natural Gas Corporation
of India.
REFERENCES
1. Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PBS,
Gallie BL. Profiling genomic copy number changes in
retinoblastoma beyond loss of RB1. Genes Chromosomes
Cancer 2007; 46:118-29. [PMID: 17099872]
2. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 are a
candidate oncogene in the 1q minimal region of genomic gain
in multiple cancers. Oncogene 2005; 24:4741-53. [PMID:
15897902]
3. Grasemann C, Gratias S, Stephan H. Schu¨ ler A, Schramm A,
Hitpass LK, Rieder H, Schneider S, Kappes F, Eggert A and
Lohmann DR. Gains and overexpression identify DEK and
E2F3 as targets of chromosome 6p gains in retinoblastoma.
Oncogene 2005; 24:6441-9. [PMID: 16007192]
4. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis
of 6p22 genomic gain in retinoblastoma. Genes
Chromosomes Cancer 2006; 45:72-82. [PMID: 16180235]
Figure 2. KIF14 and E2F3 expression in tumor and control retina. A and D show no immunoreactivity of KIF14 and E2F3 in non-neoplastic
retina. B and C show positive nucleocytoplasm (arrow heads) and nuclear (arrows) expression of KIF14 in tumor cells. E and F show positive
nuclear (arrows) expression of E2F3 in tumor cells. All are 3,3′-diaminobenzidine staining with hematoxylin counterstain. The pictures were
taken under 40X magnification.
Molecular Vision 2009; 15:235-240 <http://www.molvis.org/molvis/v15/a23> © 2009 Molecular Vision
239
5. Madhavan J, Coral K, Mallikarjuna K, Corson TW, Amit N,
Khetan V, George R, Biswas J, Gallie BL,
Kumaramanickavel G. High expression of KIF14 gene in
human retinoblastoma: association with older age at
diagnosis. Invest Ophthalmol Vis Sci 2007; 48:4901-5.
[PMID: 17962437]
6. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg
EA, Barr FA. KIF14 and citron kinase act together to promote
efficient cytokinesis. J Cell Biol 2006; 172:363-72. [PMID:
16431929]
7. Pearson BE, Nasheuer HP, Wang TS. Human DNA polymerase
alpha gene: sequences controlling expression in cycling and
serum-stimulated cells. Mol Cell Biol 1991; 11:2081-95.
[PMID: 2005899]
8. Fry CJ, Slansky JE, Farnham PJ. Position-dependent
transcriptional regulation of the murine dihydrofolate
reductase promoter by the E2F transactivation domain. Mol
Cell Biol 1997; 17:1966-76. [PMID: 9121444]
9. Bruch J, Schulz WA, Haussler J, Melzner I, Bruderlein S,
Moller P, Kemmerling R, Vogel W, Hameister H. Delineation
of the 6p22 amplification unit in urinary bladder carcinoma
cell lines. Cancer Res 2000; 60:4526-30. [PMID: 10969802]
10. Finger PT, Harbour JW, Karcioglu ZA. Risk Factors for
Metastasis in Retinoblastoma. Surv Ophthalmol 2002;
47:1-16. [PMID: 11801265]
11. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE,
Radlwimmer B, Lohmann DR, Lichter P. Detection of
chromosomal imbalances in retinoblastoma by matrix-based
comparative genomic hybridization. Genes Chromosomes
Cancer 2005; 43:294-301. [PMID: 15834944]
12. Lillington DM, Kingston JE, Coen PG, Price E, Hungerford J,
Domizio P, Young BD, Onadim Z. Comparative genomic
hybridization of 49 primary retinoblastoma tumors identifies
chromosomal regions associated with histopathology,
progression, and patient outcome. Genes Chromosomes
Cancer 2003; 36:121-8. [PMID: 12508240]
13. Mairal A, Pinglier E, Gilbert E, Peter M, Validire P, Desjardins
L, Doz F, Aurias A, Couturier J. Detection of chromosome
imbalances in retinoblastoma by parallel karyotype and CGH
analyses. Genes Chromosomes Cancer 2000; 28:370-9.
[PMID: 10862045]
14. Herzog S, Lohmann DR, Buiting K, Schüler A, Horsthemke B,
Rehder H, Rieder H. Marked differences in unilateral isolated
retinoblastomas from young and older children studied by
comparative genomic hybridization. Hum Genet 2001;
108:98-104. [PMID: 11281459]
15. Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C,
Marshall CG, Fernandes C, Annis J, Linsley PS. RNA
interference-mediated silencing of mitotic kinesin KIF14
disrupts cell cycle progression and induces cytokinesis
failure. Mol Cell Biol 2006; 26:3853-63. [PMID: 16648480]
16. Saavedra HI, Wu L, de Bruin A, Timmers C, Thomas RJ,
Michael W, Michael RL, Gustavo L. Specificity of E2F1,
E2F2 and E2F3 in mediating phenotypes induced by loss of
Rb. Cell Growth Differ 2002; 13:215-25. [PMID: 12065245]
Molecular Vision 2009; 15:235-240 <http://www.molvis.org/molvis/v15/a23> © 2009 Molecular Vision
The print version of this article was created on 21 January 2009. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
240
